Human Variation‐Informed Prioritization of MPHOSPH6 in Lung Adenocarcinoma: A Source‐Aware Multiomics Evidence Framework
Chongwen Fang, Min Wu, Jing Lv, Yanping Zhang, Qinyun Zheng, Xiang Shen, Shangke Huang · 2026
Read Human Variation‐Informed Prioritization of MPHOSPH6 in Lung Adenocarcinoma: A Source‐Aware Multiomics Evidence Framework by Chongwen Fang, Min Wu, Jing Lv, Yanping Zhang, Qinyun Zheng, Xiang Shen, Shangke Huang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13537304.txt.
Description
Chongwen Fang and co-authors test a gene called MPHOSPH6 as a possible marker for lung adenocarcinoma in a 2026 study. Marker claims often mix weak and strong proof, so the team built a frame that keeps each kind of proof apart. They checked set DNA variants, gene-level links, cell data, drug tests, and known protein shape facts. Each class had to stand on its own.
Some proof held up and some did not. Five of six set variants passed a strict bar in one data set, and two matched in a second data set. Gene-level tests linked higher gene activity to higher risk, yet cell tests in tumors showed no clear gap. Drug tests lost force once repeat-test fixes were applied. The authors close with a narrow claim: the gene earns lab follow-up, but it is not yet a proven marker or drug target.
Catalog record
| CREATOR | Chongwen Fang, Min Wu, Jing Lv, Yanping Zhang, Qinyun Zheng, Xiang Shen, Shangke Huang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |